Form 8-K - Current report:
SEC Accession No. 0001104659-26-018128
Filing Date
2026-02-20
Accepted
2026-02-20 16:02:24
Documents
14
Period of Report
2026-02-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fencf-20260220x8k.htm   iXBRL 8-K 53570
2 EX-99.1 fencf-20260220xex99d1.htm EX-99.1 41827
3 GRAPHIC fencf-20260220xex99d1001.jpg GRAPHIC 2446
  Complete submission text file 0001104659-26-018128.txt   222523

Data Files

Seq Description Document Type Size
4 EX-101.SCH fencf-20260220.xsd EX-101.SCH 2667
5 EX-101.LAB fencf-20260220_lab.xml EX-101.LAB 15923
6 EX-101.PRE fencf-20260220_pre.xml EX-101.PRE 10312
16 EXTRACTED XBRL INSTANCE DOCUMENT fencf-20260220x8k_htm.xml XML 4872
Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Filer) CIK: 0001211583 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32295 | Film No.: 26659724
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)